Pernix Therapeutics To Present At The 24th Annual ROTH Conference
Pernix Therapeutics Holdings, Inc. (NYSE Amex: PTX), a specialty
pharmaceutical company, today announced that Cooper Collins, President
and Chief Executive Officer, will present at the 24
ROTH Conference on...
Pernix Therapeutics Holdings, Inc. (NYSE Amex: PTX), a specialty pharmaceutical company, today announced that Cooper Collins, President and Chief Executive Officer, will present at the 24 th Annual ROTH Conference on Tuesday, March 13, 2012 at 10:30 a.m. PST. The conference will be held at The Ritz Carlton in Dana Point, CA. The presentation will be broadcast live over the Internet and can be accessed on the Company’s website, www.pernixtx.com, under “Webcasts and Presentation” on the investor relations section. The audio-recording of the presentation will be archived on the Company’s website for approximately 30 days following the conclusion of the presentation. About Pernix Therapeutics Holdings, Inc. Pernix Therapeutics Holdings, Inc. is a specialty pharmaceutical company primarily focused on the sales, marketing, and development of branded and generic pharmaceutical products. The Company manages a portfolio of branded and generic products and Theobromine, a non-codeine, cough suppressant product candidate in development. The Company’s branded products for the pediatrics market include CEDAX®, an antibiotic for middle ear infections, Natroba™, a topical treatment for head lice marketed under an exclusive co-promotion agreement with ParaPRO, LLC and a family of prescription treatments for cough and cold (Brovex®, Aldex® and Pediatex®). The Company promotes its branded products through an established U.S. sales force. Pernix also markets generic products through its wholly-owned subsidiary, Macoven Pharmaceuticals. Founded in 1996, the Company is based in The Woodlands, TX. Additional information about Pernix is available on the Company’s website located at www.pernixtx.com.